Prabotulinumtoxin A

CHEMBL4297229 Phase 4 Aprobado Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

Prabotulinumtoxin A is a botulinum toxin type A product that acts by inhibiting the release of acetylcholine at the neuromuscular junction through cleavage of the SNAP-25 protein, causing temporary, localized muscle paralysis. It is approved for the treatment of chronic migraine prophylaxis and cosmetic treatment of glabellar lines.

Áreas terapéuticas

Mecanismo de acción

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Prabotulinumtoxin A is a botulinum toxin type A product that acts by inhibiting the release of acetylcholine at the neuromuscular junction through cleavage of the SNAP-25 protein, causing temporary, localized muscle paralysis. It is approved for the treatment of chronic migraine prophylaxis and cosmetic treatment of glabellar lines.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Prabotulinumtoxin A is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297229. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.